![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Perceived Barriers Related to the Management of HCVInfection Among Physicians Prescribing Opioid Agonist Therapy:The C-SCOPE Study
|
|
|
Reported by Jules Levin
AASLD: The Liver Meeting 2017; Washington, DC, USA; October 20-24, 2017.
Alain H Litwin1; Martine Drolet2; Chizoba Nwankwo3; Marta Torrens4; Andrej Kastelic5; Stephan Walcher6; Lorenzo Somaini7; Emily Mulvihill8; Jochen Ertl8; Jason Grebely9
1Albert Einstein College of Medicine and Montefiore Medical Center, New York, NY, USA; 2Merck Canada Inc., Montreal, Canada; 3Merck & Co., Inc., Kenilworth, NJ, USA; 4Institute of Neuropsychiatry and Addictions, IMIM (Hospital del Mar Medical Research Institute) and Department of Psychiatry, Universitat Autònoma de Barcelona, Barcelona, Spain; 5National Centre for Treatment of Drug Addiction, University Psychiatric Clinic Ljubljana, Slovenia, EU; 6CONCEPT, Center for Addiction-Medicine, Munich, Germany; 7Addiction Treatment Centre Local Health Unit ASL Biella, Biella, Italy; 8Kantar Health, St. Louis, MO, USA; 9The Kirby Institute, UNSW Sydney, Sydney, Australia
![1023171](../images/102317/102317-1/1023171.gif)
![1023172](../images/102317/102317-1/1023172.gif)
![1023173](../images/102317/102317-1/1023173.gif)
![1023174](../images/102317/102317-1/1023174.gif)
![1023175](../images/102317/102317-1/1023175.gif)
![1023176](../images/102317/102317-1/1023176.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|